{"entity":{"id":"takeda","kind":"company","name":"Takeda","aka":["Millennium Pharmaceuticals","Ariad Pharmaceuticals","ARIAD","Nycomed","Shire"],"tldr":"Takeda co-owns Adcetris outside the US and is developing STING-agonist conjugates and CAR-NK cells.","summary":"Takeda, based in Tokyo and listed as 4502.T, co-owns Adcetris, or brentuximab vedotin, outside the United States and is developing STING-agonist antibody conjugates and cord-blood CAR-NK cells with MD Anderson. Its oncology portfolio also includes bortezomib, brigatinib, fruquintinib and anagrelide, while mobocertinib was withdrawn, and TAK-500 is its STING immune-stimulating antibody conjugate. OnCo links it to the ECHELON-1 paper, in which brentuximab vedotin replaced bleomycin in first-line Hodgkin lymphoma chemotherapy, to Hutchmed and Innovent as partners, and to Takeda Ventures. Whether off-the-shelf CAR-NK cells can match autologous CAR-T on durability is the open question behind its MD Anderson collaboration. Brentuximab vedotin has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.takeda.com"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","immunotherapy"],"technologies":[],"targets":[],"drugs":["brentuximab-vedotin","tak-928","elritercept","sapanisertib","serabelisib","human-normal-immunoglobulin"],"companies":["takeda-ventures"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04129502","nct06390995","nct05020015","nct02979522","nct07648030","nct07436728","nct06980480","nct02716116","nct05673785","nct07205718"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Tokyo","country":"JP","companyType":"pharma","website":"https://www.takeda.com","ticker":"4502.T","investors":[],"funding":[]},"route":"/companies/takeda/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/"},{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/"},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/"},{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/"},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/"},{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/"},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/"},{"id":"orteronel","kind":"drug","name":"Orteronel","route":"/drugs/orteronel/"},{"id":"pevonedistat","kind":"drug","name":"Pevonedistat","route":"/drugs/pevonedistat/"},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/"},{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/"},{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/"},{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/"},{"id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"company":[{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/"},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/"},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"},{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/"},{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","route":"/companies/takeda-ventures/"}],"trial":[{"id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/"},{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/"},{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/"},{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/"},{"id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/"},{"id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/"},{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/"},{"id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/"},{"id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/"},{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct02716116/"},{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/"},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/"},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/"},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/"},{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/"},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/"},{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/"},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/"},{"id":"nct03268954","kind":"trial","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","route":"/trials/nct03268954/"},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/"},{"id":"nct04129502","kind":"trial","name":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct04129502/"},{"id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"paper":[{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/"},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/"}]}}